Opioids Market Outlook:
Opioids Market size was valued at USD 23.09 billion in 2024 and is projected to reach USD 26.80 billion by the end of 2034, rising at a CAGR of 2.1% during the forecast period, i.e., 2025-2034. In 2025, the industry size of opioids is assessed at USD 23.40 billion.
In the U.S., there were an estimated 51 million adults with chronic pain in 2023. As a result, there is a substantial population of patients utilizing opioids through managed care and hospital systems. In 2021-2022, U.S. outpatient prescription opioid use resulted in 68.1 million prescription fills. Oxycodone and hydrocodone accounted for roughly 74% of the overall expenses. Medicare funded about 38.1% of opioid expenditures. Another consideration is that federal regulations surrounding quotas for APIs may limit the capacity for production. This raises issues around market concentration and supply resilience. Commodity pricing reflects moderate inflation. While there is no specific PPI and CPI data made available for opioid products. RDD investment is evident in FDA and NIH action as well. For instance, the first auto-injector for opioid overdose reversal, Zurnai, was approved in August 2024 after research at scale through NIH.
